Study of intravesical mitomycin C in patients with multiple prior occurrences of superficial bladder cancer.
A limited course of intravesical mitomycin C was tested in 12 patients who had at least three, and an average of six, occurrences of superficial bladder cancer, and were at high risk for subsequent recurrences. After intravesical chemotherapy, recurrence rates were significantly less than rates prior to chemotherapy.